Biotech · Private company
Anthos Therapeutics, Inc.
Track this companyFree. Adds Anthos Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials62 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- AbelacimabPhase 3 · Atrial Fibrillation (AF)ClinicalTrials.gov · fetched Nov 12, 2026
- AbelacimabPhase 3 · Venous ThromboembolismClinicalTrials.gov · fetched Nov 12, 2026
- ApixabanPhase 3 · Venous ThromboembolismClinicalTrials.gov · fetched Nov 12, 2026
- DalteparinPhase 3 · Venous ThromboembolismClinicalTrials.gov · fetched Nov 12, 2026
- MAA868 Cohort 1Phase 2 · Atrial FibrillationClinicalTrials.gov · fetched Nov 12, 2026
- MAA868 Cohort 2Phase 2 · Atrial FibrillationClinicalTrials.gov · fetched Nov 12, 2026
- MAA868 Cohort 3Phase 2 · Atrial FibrillationClinicalTrials.gov · fetched Nov 12, 2026
- RivaroxabanPhase 2 · Atrial Fibrillation (AF)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)PHASE3 · RECRUITING · started Dec 27, 2022ClinicalTrials.gov NCT05712200 · fetched Nov 12, 2026
- A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTEPHASE3 · TERMINATED · started Sep 27, 2022ClinicalTrials.gov NCT05171075 · fetched Nov 12, 2026
- Study in Atrial Fibrillation (AF) Patients at High Risk of StrokeTERMINATED · started Sep 14, 2022ClinicalTrials.gov NCT05421533 · fetched Nov 12, 2026
- A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTEPHASE3 · TERMINATED · started May 5, 2022ClinicalTrials.gov NCT05171049 · fetched Nov 12, 2026
- Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial FibrillationPHASE2 · ACTIVE_NOT_RECRUITING · started Feb 2, 2021ClinicalTrials.gov NCT04755283 · fetched Nov 12, 2026
- A Dose-range Finding Study of MAA868 in Patients With Atrial FibrillationPHASE2 · COMPLETED · started Dec 11, 2019ClinicalTrials.gov NCT04213807 · fetched Nov 12, 2026